Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Cyclacel Pharmaceuticals, Inc is a biotechnology business based in the US. Cyclacel Pharmaceuticals shares (CYCC) are listed on the NASDAQ and all prices are listed in US Dollars. Cyclacel Pharmaceuticals employs 12 staff and has a trailing 12-month revenue of around USD$150,000.
|Latest market close||USD$4.32|
|52-week range||USD$3.12 - USD$19.598|
|50-day moving average||USD$4.2094|
|200-day moving average||USD$4.1431|
|Wall St. target price||USD$21.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.573|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||-54.67%|
|1 month (2020-12-18)||2.13%|
|3 months (2020-10-16)||11.05%|
|6 months (2020-07-17)||-3.57%|
|1 year (2020-01-17)||440.00%|
|2 years (2019-01-18)||460.24%|
|3 years (2018-01-18)||157.14%|
|5 years (2016-01-15)||1,067.57%|
Valuing Cyclacel Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cyclacel Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cyclacel Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Cyclacel Pharmaceuticals shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||USD$-4,658,000|
|Return on assets TTM||-28.96%|
|Return on equity TTM||-41.5%|
|Market capitalisation||USD$39 million|
TTM: trailing 12 months
There are currently 211,723 Cyclacel Pharmaceuticals shares held short by investors – that's known as Cyclacel Pharmaceuticals's "short interest". This figure is 221.7% up from 65,816 last month.
There are a few different ways that this level of interest in shorting Cyclacel Pharmaceuticals shares can be evaluated.
Cyclacel Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Cyclacel Pharmaceuticals shares currently shorted divided by the average quantity of Cyclacel Pharmaceuticals shares traded daily (recently around 170744.35483871). Cyclacel Pharmaceuticals's SIR currently stands at 1.24. In other words for every 100,000 Cyclacel Pharmaceuticals shares traded daily on the market, roughly 1240 shares are currently held short.
However Cyclacel Pharmaceuticals's short interest can also be evaluated against the total number of Cyclacel Pharmaceuticals shares, or, against the total number of tradable Cyclacel Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cyclacel Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Cyclacel Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0439% of the tradable shares (for every 100,000 tradable Cyclacel Pharmaceuticals shares, roughly 44 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cyclacel Pharmaceuticals.
Find out more about how you can short Cyclacel Pharmaceuticals stock.
We're not expecting Cyclacel Pharmaceuticals to pay a dividend over the next 12 months.
Cyclacel Pharmaceuticals's shares were split on a 1:20 basis on 15 April 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cyclacel Pharmaceuticals shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Cyclacel Pharmaceuticals shares which in turn could have impacted Cyclacel Pharmaceuticals's share price.
Over the last 12 months, Cyclacel Pharmaceuticals's shares have ranged in value from as little as $3.12 up to $19.598. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cyclacel Pharmaceuticals's is 1.1696. This would suggest that Cyclacel Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.